This study evaluated Seraph-100 hemoperfusion (HP) as a treatment for sepsis in intensive care unit (ICU) patients admitted after cardiac surgery for infective endocarditis (IE).

Thirteen septic patients received Seraph-100 HP and were compared to a control group of fifteen patients not treated with HP. Pathogen load was assessed before and after 4 hours of HP.

Using the difference in quantitative polymerase chain reaction cycle threshold (∆Cq) as a surrogate marker, the study found a significant decrease in bacterial load after Seraph-100 HP, with a mean ∆Cq of 4.6 ± 2.4, corroborated by conventional hemoculture results.

Field Emission Scanning Electron Microscopy confirmed the Seraph device’s adsorptive properties.

Clinically, the Seraph-100 group showed significant decreases in procalcitonin, C reactive protein, and lactates. This was associated with improvements in patient outcomes, including a reduced ICU stay. Notably, the incidence of acute kidney injury (AKI) requiring renal replacement therapy (RRT) was significantly lower in the HP group (15%) compared to the control group (40%).

Furthermore, Seraph-100 HP led to decreased vasopressor requirements, improved hemodynamic stability, and a reduction in AKI and RRT, ultimately improving the overall clinical course.

Read More